

1 AN ACT relating to Kentucky's electronic system for monitoring controlled
2 substances.

3 ***Be it enacted by the General Assembly of the Commonwealth of Kentucky:***

4 ➔Section 1. KRS 218A.202 is amended to read as follows:

5 (1) The Cabinet for Health and Family Services shall establish and maintain an
6 electronic system for monitoring Schedules II, III, IV, and V controlled substances.
7 The cabinet may contract for the design, upgrade, or operation of this system if the
8 contract preserves all of the rights, privileges, and protections guaranteed to
9 Kentucky citizens under this chapter and the contract requires that all other aspects
10 of the system be operated in conformity with the requirements of this or any other
11 applicable state or federal law.

12 (2) A practitioner or a pharmacist authorized to prescribe or dispense controlled
13 substances to humans shall register with the cabinet to use the system provided for
14 in this section and shall maintain such registration continuously during the
15 practitioner's or pharmacist's term of licensure and shall not have to pay a fee or tax
16 specifically dedicated to the operation of the system.

17 (3) Every practitioner or pharmacy which dispenses a controlled substance to a person
18 in Kentucky, or to a person at an address in Kentucky, shall report to the Cabinet for
19 Health and Family Services the data required by this section, which includes the
20 reporting of any Schedule II controlled substance dispensed at a facility licensed by
21 the cabinet and a Schedule II through Schedule V controlled substance regardless of
22 dosage when dispensed by the emergency department of a hospital to an emergency
23 department patient. Reporting shall not be required for:

24 (a) A drug administered directly to a patient in a hospital, a resident of a health
25 care facility licensed under KRS Chapter 216B, a resident of a child-caring
26 facility as defined by KRS 199.011, or an individual in a jail, correctional
27 facility, or juvenile detention facility;

- 1 (b) A Schedule III through Schedule V controlled substance dispensed by a
2 facility licensed by the cabinet provided that the quantity dispensed is limited
3 to an amount adequate to treat the patient for a maximum of forty-eight (48)
4 hours and is not dispensed by the emergency department of a hospital; or
- 5 (c) A drug administered or dispensed to a research subject enrolled in a research
6 protocol approved by an institutional review board that has an active
7 federalwide assurance number from the United States Department of Health
8 and Human Services, Office for Human Research Protections, where the
9 research involves single, double, or triple blind drug administration or is
10 additionally covered by a certificate of confidentiality from the National
11 Institutes of Health.
- 12 (4) In addition to the data required by subsection (5) of this section, a Kentucky-
13 licensed acute care hospital or critical access hospital shall report to the cabinet all
14 positive toxicology screens that were performed by the hospital's emergency
15 department to evaluate the patient's suspected drug overdose.
- 16 (5) Data for each controlled substance that is reported shall include but not be limited
17 to the following:
- 18 (a) Patient identifier;
19 (b) National drug code of the drug dispensed;
20 (c) Date of dispensing;
21 (d) Quantity dispensed;
22 (e) Prescriber; and
23 (f) Dispenser.
- 24 (6) The data shall be provided in the electronic format specified by the Cabinet for
25 Health and Family Services unless a waiver has been granted by the cabinet to an
26 individual dispenser. The cabinet shall establish acceptable error tolerance rates for
27 data. Dispensers shall ensure that reports fall within these tolerances. Incomplete or

1 inaccurate data shall be corrected upon notification by the cabinet if the dispenser
2 exceeds these error tolerance rates.

3 (7) The Cabinet for Health and Family Services shall only disclose data to persons and
4 entities authorized to receive that data under this section. Disclosure to any other
5 person or entity, including disclosure in the context of a civil action where the
6 disclosure is sought either for the purpose of discovery or for evidence, is prohibited
7 unless specifically authorized by this section. The Cabinet for Health and Family
8 Services shall be authorized to provide data to:

9 (a) A designated representative of a board responsible for the licensure,
10 regulation, or discipline of practitioners, pharmacists, or other person who is
11 authorized to prescribe, administer, or dispense controlled substances and who
12 is involved in a bona fide specific investigation involving a designated person;

13 (b) Employees of the Office of the Inspector General of the Cabinet for Health
14 and Family Services who have successfully completed training for the
15 electronic system and who have been approved to use the system, federal
16 prosecutors, Kentucky Commonwealth's attorneys and assistant
17 Commonwealth's attorneys, county attorneys and assistant county attorneys, a
18 peace officer certified pursuant to KRS 15.380 to 15.404, a certified or full-
19 time peace officer of another state, or a federal agent whose duty is to enforce
20 the laws of this Commonwealth, of another state, or of the United States
21 relating to drugs and who is engaged in a bona fide specific investigation
22 involving a designated person;

23 (c) A state-operated Medicaid program in conformity with subsection (8) of this
24 section;

25 (d) A properly convened grand jury pursuant to a subpoena properly issued for the
26 records;

27 (e) A practitioner or pharmacist, or employee of the practitioner's or pharmacist's

1 practice acting under the specific direction of the practitioner or pharmacist,
2 who certifies that the requested information is for the purpose of:

- 3 1. Providing medical or pharmaceutical treatment to a bona fide current or
4 prospective patient;
- 5 2. Reviewing data on controlled substances that have been reported for the
6 birth mother of an infant who is currently being treated by the
7 practitioner for neonatal abstinence syndrome, or has symptoms that
8 suggest prenatal drug exposure; or
- 9 3. Reviewing and assessing the individual prescribing or dispensing
10 patterns of the practitioner or pharmacist or to determine the accuracy
11 and completeness of information contained in the monitoring system;

12 (f) The chief medical officer of a hospital or long-term-care facility, an employee
13 of the hospital or long-term-care facility as designated by the chief medical
14 officer and who is working under his or her specific direction, or a physician
15 designee if the hospital or facility has no chief medical officer, if the officer,
16 employee, or designee certifies that the requested information is for the
17 purpose of providing medical or pharmaceutical treatment to a bona fide
18 current or prospective patient or resident in the hospital or facility;

19 (g) In addition to the purposes authorized under paragraph (a) of this subsection,
20 the Kentucky Board of Medical Licensure, for any physician who is:

- 21 1. Associated in a partnership or other business entity with a physician who
22 is already under investigation by the Board of Medical Licensure for
23 improper prescribing or dispensing practices;
- 24 2. In a designated geographic area for which a trend report indicates a
25 substantial likelihood that inappropriate prescribing or dispensing may
26 be occurring; or
- 27 3. In a designated geographic area for which a report on another physician

1 in that area indicates a substantial likelihood that inappropriate
2 prescribing or dispensing may be occurring in that area;

3 (h) In addition to the purposes authorized under paragraph (a) of this subsection,
4 the Kentucky Board of Nursing, for any advanced practice registered nurse
5 who is:

6 1. Associated in a partnership or other business entity with a physician who
7 is already under investigation by the Kentucky Board of Medical
8 Licensure for improper prescribing or dispensing practices;

9 2. Associated in a partnership or other business entity with an advanced
10 practice registered nurse who is already under investigation by the Board
11 of Nursing for improper prescribing practices;

12 3. In a designated geographic area for which a trend report indicates a
13 substantial likelihood that inappropriate prescribing or dispensing may
14 be occurring; or

15 4. In a designated geographic area for which a report on a physician or
16 another advanced practice registered nurse in that area indicates a
17 substantial likelihood that inappropriate prescribing or dispensing may
18 be occurring in that area;

19 (i) A judge or a probation or parole officer administering a diversion or probation
20 program of a criminal defendant arising out of a violation of this chapter or of
21 a criminal defendant who is documented by the court as a substance abuser
22 who is eligible to participate in a court-ordered drug diversion or probation
23 program; or

24 (j) A medical examiner engaged in a death investigation pursuant to KRS 72.026.

25 (8) The Department for Medicaid Services shall use any data or reports from the system
26 for the purpose of identifying Medicaid providers or recipients whose prescribing,
27 dispensing, or usage of controlled substances may be:

- 1 (a) Appropriately managed by a single outpatient pharmacy or primary care
2 physician; or
- 3 (b) Indicative of improper, inappropriate, or illegal prescribing or dispensing
4 practices by a practitioner or drug seeking by a Medicaid recipient.
- 5 (9) A person who receives data or any report of the system from the cabinet shall not
6 provide it to any other person or entity except as provided in this section, in another
7 statute, or by order of a court of competent jurisdiction and only to a person or
8 entity authorized to receive the data or the report under this section, except that:
- 9 (a) A person specified in subsection (7)(b) of this section who is authorized to
10 receive data or a report may share that information with any other persons
11 specified in subsection (7)(b) of this section authorized to receive data or a
12 report if the persons specified in subsection (7)(b) of this section are working
13 on a bona fide specific investigation involving a designated person. Both the
14 person providing and the person receiving the data or report under this
15 paragraph shall document in writing each person to whom the data or report
16 has been given or received and the day, month, and year that the data or report
17 has been given or received. This document shall be maintained in a file by
18 each agency engaged in the investigation;
- 19 (b) A representative of the Department for Medicaid Services may share data or
20 reports regarding overutilization by Medicaid recipients with a board
21 designated in subsection (7)(a) of this section, or with a law enforcement
22 officer designated in subsection (7)(b) of this section;
- 23 (c) The Department for Medicaid Services may submit the data as evidence in an
24 administrative hearing held in accordance with KRS Chapter 13B;
- 25 (d) If a state licensing board as defined in KRS 218A.205 initiates formal
26 disciplinary proceedings against a licensee, and data obtained by the board is
27 relevant to the charges, the board may provide the data to the licensee and his

- 1 or her counsel, as part of the notice process required by KRS 13B.050, and
2 admit the data as evidence in an administrative hearing conducted pursuant to
3 KRS Chapter 13B, with the board and licensee taking all necessary steps to
4 prevent further disclosure of the data; and
- 5 (e) A practitioner, pharmacist, or employee who obtains data under subsection
6 (7)(e) of this section may share the report with the patient or person authorized
7 to act on the patient's behalf. Any practitioner, pharmacist, or employee who
8 obtains data under subsection (7)(e) of this section may place the report in the
9 patient's medical record, in which case the individual report shall then be
10 deemed a medical record subject to disclosure on the same terms and
11 conditions as an ordinary medical record in lieu of the disclosure restrictions
12 otherwise imposed by this section.
- 13 (10) The Cabinet for Health and Family Services, all peace officers specified in
14 subsection (7)(b) of this section, all officers of the court, and all regulatory agencies
15 and officers, in using the data for investigative or prosecution purposes, shall
16 consider the nature of the prescriber's and dispenser's practice and the condition for
17 which the patient is being treated.
- 18 (11) The data and any report obtained therefrom shall not be a public record, except that
19 the Department for Medicaid Services may submit the data as evidence in an
20 administrative hearing held in accordance with KRS Chapter 13B.
- 21 (12) Intentional failure to comply with the reporting requirements of this section shall be
22 a Class B misdemeanor for the first offense and a Class A misdemeanor for each
23 subsequent offense.
- 24 (13) Intentional disclosure of transmitted data to a person not authorized by subsections
25 (7) to (9) of this section or authorized by KRS 315.121, or obtaining information
26 under this section not relating to a bona fide current or prospective patient or a bona
27 fide specific investigation, shall be a Class B misdemeanor for the first offense and

1 a Class A misdemeanor for each subsequent offense.

2 (14) The Cabinet for Health and Family Services may, by promulgating an
3 administrative regulation, limit the length of time that data remain in the electronic
4 system. Any data removed from the system shall be archived and subject to retrieval
5 within a reasonable time after a request from a person authorized to review data
6 under this section.

7 (15) (a) The Cabinet for Health and Family Services shall work with each board
8 responsible for the licensure, regulation, or discipline of practitioners,
9 pharmacists, or other persons who are authorized to prescribe, administer, or
10 dispense controlled substances for the development of a continuing education
11 program about the purposes and uses of the electronic system for monitoring
12 established in this section.

13 (b) The cabinet shall work with the Kentucky Bar Association for the
14 development of a continuing education program for attorneys about the
15 purposes and uses of the electronic system for monitoring established in this
16 section.

17 (c) The cabinet shall work with the Justice and Public Safety Cabinet for the
18 development of a continuing education program for law enforcement officers
19 about the purposes and uses of the electronic system for monitoring
20 established in this section.

21 (16) If the cabinet becomes aware of a prescriber's or dispenser's failure to comply with
22 this section, the cabinet shall notify the licensing board or agency responsible for
23 licensing the prescriber or dispenser. The licensing board shall treat the notification
24 as a complaint against the licensee.

25 (17) The Cabinet for Health and Family Services, Office of Inspector General, shall
26 conduct quarterly reviews to identify patterns of potential improper, inappropriate,
27 or illegal prescribing or dispensing of a controlled substance. The Office of

1 Inspector General may independently investigate and submit findings and
2 recommendations to the appropriate boards of licensure or other reporting agencies.

3 (18) The cabinet shall promulgate administrative regulations to implement the provisions
4 of this section. Included in these administrative regulations shall be:

5 (a) An error resolution process allowing a patient to whom a report had been
6 disclosed under subsection (9) of this section to request the correction of
7 inaccurate information contained in the system relating to that patient; and

8 (b) A requirement that data be reported to the system under subsection (3) of this
9 section within one (1) day of dispensing.

10 (19) Before July 1, 2018, the Administrative Office of the Courts shall forward data
11 regarding any felony or Class A misdemeanor conviction that involves the
12 trafficking or possession of a controlled substance or other prohibited acts under
13 KRS Chapter 218A for the previous five (5) calendar years to the cabinet for
14 inclusion in the electronic monitoring system established under this section. On or
15 after July 1, 2018 such data shall be forwarded by the Administrative Office of the
16 Courts to the cabinet on a continuing basis. The cabinet shall incorporate the data
17 received into the system so that a query by patient name indicates any prior drug
18 conviction.

19 **(20) By July 1, 2020, the Cabinet for Health and Family Services shall establish**
20 **secure connections between the electronic system for monitoring controlled**
21 **substances established in this section and all prescribing or dispensing health**
22 **care practitioners' electronic health recordkeeping systems to allow viewing of**
23 **information within the electronic system for monitoring controlled substances**
24 **established in this section. The Cabinet for Health and Family Services may enter**
25 **into agreements or contracts to establish these secure connections. The owner or**
26 **license holder of a prescribing or dispensing health care practitioner's electronic**
27 **health recordkeeping system shall be responsible for ensuring that only**

1 authorized individuals shall have access to information within the electronic
2 system for monitoring controlled substances established in this section. The
3 secure connecting service shall:

4 (a) Receive and transmit information from all states contiguous to Kentucky, as
5 well as other states to be determined, and deliver this information to the
6 health care practitioners via their respective electronic health recordkeeping
7 systems. Such information sharing with other states shall be based on the
8 most expedient method accessible to the concerned states by which to begin
9 sharing relevant data;

10 (b) Prior to a request for the information from the electronic system for
11 monitoring controlled substances established in this section, determine the
12 authorization of the receiving health care practitioner, as established in this
13 section, so as to increase the speed of the availability of the information;

14 (c) Have the capability of providing opioid treatment agreements, that have
15 been entered into by the relevant patient, to the health care practitioners
16 authorized to receive this information; and

17 (d) Duplicate all information delivered by the service into the electronic system
18 for monitoring controlled substances established in this section.